CUAMC
KALV

China Universal Asset Management Company’s KalVista Pharmaceuticals KALV Stock Holding History

China Universal Asset Management Company’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,970
Closed -$181K – 529
2026
Q1 		$181K Buy
8,970
+734
+9% +$11.8K 0.01% 360
2025
Q4 		$133K Sell
8,236
-588
-7% -$7.79K 0.01% 387
2025
Q3 		$107K Sell
8,824
-1,161
-12% -$16K 0.01% 385
2025
Q2 		$113K Buy
9,985
+73
+0.7% +$892 0.01% 356
2025
Q1 		$114K Sell
9,912
-417
-4% -$4.26K 0.01% 351
2024
Q4 		$87.5K Buy
10,329
+2,043
+25% +$21.2K 0.01% 408
2024
Q3 		$96K Buy
8,286
+3,328
+67% +$41.9K 0.01% 358
2024
Q2 		$58.4K Sell
4,958
-3,066
-38% -$35.8K 0.01% 346
2024
Q1 		$95.2K Buy
8,024
+4,043
+102% +$53.9K 0.01% 378
2023
Q4 		$48.8K Buy
+3,981
New +$36.2K 0.01% 371
2022
Q4 		– Sell
-230
Closed -$3K – 424
2022
Q3 		$3K Buy
+230
New +$3.21K ﹤0.01% 328

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

China Universal Asset Management Company's KALV Position: Q2 2026 in Review

China Universal Asset Management Company sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 8,970 shares — an estimated $181K sold.

China Universal Asset Management Company first reported a position in KALV in Q3 2022 and held it in 11 quarters. The position peaked at $181K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • China Universal Asset Management Company reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • China Universal Asset Management Company sold 8,970 KalVista Pharmaceuticals shares in Q2 2026, an estimated $181K.
  • China Universal Asset Management Company first reported a position in KalVista Pharmaceuticals in Q3 2022 and held it in 11 quarters.
  • China Universal Asset Management Company's KalVista Pharmaceuticals position peaked at $181K in Q1 2026.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.